Influenza virus infection is a common infectious disease that often causes mild symptoms but can lead to severe symptoms and death. Influenza epidemics occur yearly, causing three to five million cases of severe illness, and about 250,000 to 500,000 deaths worldwide. Although the common strains of influenza constitute a significant public health concern, more dangerous influenza strains have emerged periodically leading to pandemics that kill millions of people. The high mutation rate of influenza viruses leads to the frequent emergence of new strains and also to the development of resistance to antiviral drugs. An effective antibody-based influenza drug based on iBio technology has the potential to effectively treat such drug-resistant infections as well as complex and advanced infections.
About Antibody Therapeutics
The use of monoclonal antibodies for the treatment of a wide variety of diseases and illnesses has emerged as one of the most important contributions of biotechnology to clinical medicine. A few dozen antibody products generate global annual sales of about $50 billion, and several hundred new product candidates are in clinical trials for many medical applications. Rituximab is an antibody drug approved for treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other diseases, generating annual sales in excess of $6 billion. Palivizumab is an antibody drug used to prevent serious lung infections caused
|SOURCE iBio, Inc.|
Copyright©2012 PR Newswire.
All rights reserved